CRISPR Therapeutics AG CRSP
42.24 USD -0.38 (-0.89%)
Regular-session close
42.18 -0.06 -0.14%
After hours · Nov 13, 4:55 PM ET
41.79 Day range 42.79
42.24 52-week range 61.89
- YTD
- -19.45%
- 1 year
- -17.35%
News
seekingalpha.com Crispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish Sentiment Crispr Therapeutics remains a market leader in gene-editing, with Casgevy and a robust pipeline targeting hematology, cardiovascular, autoimmune, and regenerative medicine. CRSP's revenue growth from…
benzinga.com CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy CRISPR Therapeutics reported Phase 1b data for CTX310, showing a 63% triglyceride drop and solid safety in severe hypertriglyceridemia.
globenewswire.com CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the…
benzinga.com CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver Transaminases -Data presented in a late-breaking oral presentation at AHA--A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG)…
globenewswire.com CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026 -Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG)…
benzinga.com Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all…
globenewswire.com CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all…- benzinga.com Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90 Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.
- benzinga.com Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70 Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.
benzinga.com CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 1.71 percent increase over losses…- benzinga.com CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad CRISPR Therapeutics (NASDAQ:CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the…
benzinga.com UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52 UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.
benzinga.com Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’ Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
benzinga.com Cathie Wood Says AI Revolution Could Supercharge Global Growth — TSLA, COIN and CRSP Stocks Are Among Her Top Bets Cathie Wood explains why Tesla, Coinbase, and CRISPR lead her "Rapid Real Growth" thesis as 5 tech platforms transform global GDP.
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.- benzinga.com Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
benzinga.com CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3.…
benzinga.com Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
benzinga.com Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
benzinga.com Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
benzinga.com Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88 Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.- benzinga.com CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of…
benzinga.com Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the technology-heavy Nasdaq 100 Index.
benzinga.com FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving lower in pre-market trading.
benzinga.com What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
benzinga.com Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing in 2026 as competition in blood disorders intensifies.
benzinga.com Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
benzinga.com Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.
benzinga.com My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
benzinga.com Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
benzinga.com 44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in.
benzinga.com Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.- benzinga.com 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics
benzinga.com This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday 
benzinga.com This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
benzinga.com Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - benzinga.com Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.
- benzinga.com Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.
- benzinga.com Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades' On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 - benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 75 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 258 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 348 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
- benzinga.com 39 Stocks Moving In Wednesday's Mid-Day Session Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target.